ReviewPharmaceuticals (Basel, Switzerland)2025
At 75 Years, Is Lithium the Gold Standard in Bipolar Disorder?
Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lithium was the first discovered mood stabilizer for bipolar disorder. However, several antiepileptics such as valproate and carbamazepine have also proven to be mood stabilizers in all phases of bipolar disorder with profiles barely distinguishable from lithium. Second-generation antipsychotics were slowly recognized in almost all cases to be useful in all phases of bipolar disorder. These different treatments have not been found to have any common mechanism of action. Indeed, lithium itself has numerous biochemical effects that are often not replicable. The newest biochemical effects described for lithium are exciting but are still merely promising and should not be taught to medical students as facts, especially since they do not explain the fact that several antiepileptic and second-generation antipsychotics also work well in all phases of bipolar disorder. Lithium is not specific to bipolar disorder but has uses in several other psychiatric and nonpsychiatric conditions. Lithium, like most treatments in medicine, is nonspecific; it is still useful in many cases, but is not in any sense a "gold standard".
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.